November 15th, 2026Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GISTCrossover to bezuclastinib plus sunitinib after progression on sunitinib improved PFS and responses in GIST in phase 3 PEAK, with no new safety signals.Read more